Predictors of Increased CRP Levels After Initiation of Efavirenz-Based Therapy

Female sex was associated with increased CRP levels at 96 weeks, but use of abacavir was not.

C-reactive protein (CRP) levels are associated with cardiovascular risk in the general population and with HIV disease progression among infected individuals. As part of the ACTG 5095 trial, investigators evaluated CRP levels in stored serum samples from 196 HIV-infected patients (145 men and 51 women) who achieved durable virologic suppression on first-line AZT/3TC + efavirenz, with or without abacavir.

At baseline, CRP levels did not differ significantly by sex, but at 96 weeks, women had significantly higher levels than men (median, 6.0 vs. 1.6 mg/L). The increase in CRP levels after 96 weeks of efavirenz-based treatment was significant only for women. The addition of abacavir to AZT/3TC + efavirenz had no effect on CRP levels. In a subgr…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Predictors of Increased CRP Levels After Initiation of Efavirenz-Based Therapy

Topics

Reviewing Author